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Abstract
Many proteins of the calcium-dependent (C-type) lectin family have been shown to play an important role in innate
immunity. They can bind to a broad range of carbohydrates, which enables them to interact with ligands present on the surface of
micro-organisms. We previously reported the finding of a new putative chicken lectin, which was predominantly localized to the
respiratory tract, and thus termed chicken lung lectin (cLL). In order to investigate the biochemical and biophysical properties of
cLL, the recombinant protein was expressed, affinity purified and characterized. Recombinant cLL was expressed as four
differently sized peptides, which is most likely due to post-translational modification. Crosslinking of the protein led to the
formation of two high-molecular weight products, indicating that cLL forms trimeric and possibly even multimeric subunits.
cLL was shown to have lectin activity, preferentially binding to a-mannose in a calcium-dependent manner. Furthermore, cLL
was shown to inhibit the haemagglutination-activity of human isolates of influenza A virus, subtype H3N2 and H1N1. These
result show that cLL is a true C-type lectin with a very distinct sugar specificity, and that this chicken lectin could play an
important role in innate immunity.
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1. Introduction
The innate immune system provides a first line
defense against potential pathogens, bridging the
interval between exposure to the pathogen and the
specific response of the adaptive immune system. The
effectiveness of the innate immune system highly
depends on the recognition of pathogens. For this
purpose, the innate immune system relies on pattern
recognition molecules which are capable of binding to
regular patterns of carbohydrates present on the
surface of pathogens. Within this group of pattern
recognition molecules, the calcium-dependent (C-
type) lectins represent a family of proteins which are
found throughout the animal kingdom (Day, 1994).
These proteins share a structural homology in their
carbohydrate recognition domains (CRD) but differ
with respect to their carbohydrate specificity. We
recently reported the discovery of a chicken lectin
which was designated chicken lung lectin (cLL) due to
its predominant expression in the chicken respiratory
system (Hogenkamp et al., 2006). Based on sequence
homology, cLL was identified as a C-type lectin, and
although it could not be classified as a collectin due to
its lack of a collagen domain, the sequence of its CRD
was found to be most homologous to that of the
collectin surfactant protein A (SP-A) (39–45%
similarity, depending on the species, Hogenkamp
et al., 2006). To our knowledge, no other C-type
lectins with more structural similarities to cLL have
been identified to date. Collectins and several other C-
type lectins have been identified as important
molecules in innate immunity. For example, SP-A
plays an important role in innate defense against
invading bacterial pathogens in the lung (reviewed in
Wright et al., 2001 and Hogenkamp et al., 2007), as
well as viruses, including influenza A virus (IAV).
Other lectins such as RegIIIg (Narushima et al., 1997),
and its human homologue HIP/PAP (Lasserre et al.,
1992), affect the gut flora composition and have been
shown to possess direct anti-microbial properties
(Cash et al., 2006). Tetranectin is a secreted C-type
lectin (Berglund and Petersen, 1992; Sørensen et al.,
1995) which has also been found in chicken
(unpublished data, GenBank accession no.
AJ277116). Its function is not quite clear yet, but it
has been suggested to play a role in cellular immunity
(Stoevring et al., 2005). In this study, we expressed
recombinant cLL to investigate the structural and
functional characteristics of this protein. The carbo-
hydrate specificity of cLL was tested, and the putative
protective role of cLL was studied by investigating
haemagglutination-inhibition and neutralization of
viral infectivity of various IAV strains.
2. Materials and methods
2.1. RNA extraction and cDNA synthesis
Total cellular RNA from lung tissue from healthy
female Ross 308 broiler chicken was extracted using
TRIzol# (Invitrogen, Carlsbad, CA) and Magnalyser
Green Beads (Roche Diagnostics GmbH, Mannheim,
Germany Diagnostics GmbH, Mannheim, Germany).
The cDNAs used as templates in PCR were
synthesized using 1 mg DNase I treated RNA with
M-MLV-RT and 500 mg/ml oligo dT12–18 primers
(Invitrogen, Carlsbad, CA) in a 20 ml reaction volume
with incubation at 37 8C for 50 min.
2.2. Polymerase chain reaction and amplified
DNA fragment isolation
To amplify cDNA of the mature peptide sequence of
cLL, a PCR reaction was performed using FastStart
DNA Taq-polymerase (Roche Diagnostics Gmbh,
Mannheim, Germany), cLL-specific forward primer
50-GGATCCAAACCAACACAGATTTTTCC-30, and
cLL-specific reverse primer 50-GCGGCCGCAAAC-
TGGCAGACAACAAG-30 (Hogenkamp et al., 2006).
The forward primer contained the BamHI restriction
site sequence, and cLL reverse primer contained the
NotI restriction site sequence. Amplification comprised
of initial denaturation at 95 8C for 2 min, followed by
40 cycles consisting of 95 8C for 30s, 49 8C for 30s,
72 8C for 1 min and a final extension at 72 8C for 7 min.
PCR products were analyzed by agarose gel electro-
phoresis and purified with a QIAEX agarose gel
extraction kit (Qiagen, Valencia, CA).
2.3. Cloning and sequencing of the PCR products
The purified PCR fragments were ligated into a
pCR1 4-TOPO1 plasmid vector (Invitrogen, Carls-
bad, CA). Ligated plasmids were transfected into
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TOP10 Escherichia coli cells by heatshock. Clones
were selected by growth on Luria-Bertani broth (LB)-
plates containing 100 mg/ml kanamycin. Positive
clones were screened with PCR for correct product
size and sequenced. Sequence reactionswere performed
using an ABI PRISM BigDye Terminator v3.0 Ready
Reaction Cycle Sequencing kit (Applied Biosystems,
Foster City, CA). All reactions were carried out in both
directions using the T7 and T3 primer sites and
separated on an ABI PRISM 3100 fluorescent DNA
sequencer (Applied Biosystems, Foster City, CA). cLL-
inserts were isolated from positive clones using BamHI
and NotI restriction sites and ligated into a pABC-
cystatin-hisN vector with a cystatin signal peptide and
an in-frame N-terminal His-tag.
2.4. Transfection
HEK293-EBNA cells (ATCC CRL10852) were
grown in 90% Freestyle (GIBCO; Invitrogen, Carls-
bad, CA) and 10% Ca2+-free Dulbecco’s modified
Eagle’s medium (DMEM) (GIBCO; Invitrogen,
Carlsbad, CA), containing 5% FCS (Invitrogen), 1%
pluronic (Sigma–Aldrich, St. Louis, CA), 10 mM
HEPES, 4 mM L-glutamine, 200 U/l penicillin G,
0.1 mg/l streptomycin and 50 mg/ml geneticin. Cells
were maintained in exponential growth using Erlen-
meyer flasks at 120 rpm on an orbital shaker mounted
in a Reach-In CO2 incubator (Clean Air Techniek,
Woerden, The Netherlands). HEK293-EBNA cells
were transfected using DNA–PEI (Polysciences,
Warrington, PA) according to Durocher et al.
(2002). Briefly, 24 h before transfection, cells were
seeded at 2.5  105 ml1 in medium without FCS.
The next day DNA–PEI complexes were formed by a
10 min incubation of plasmid DNA at 20 mg/ml with
PEI at 40 mg/ml in Optimem (GIBCO; Invitrogen,
Carlsbad, CA); 25 ml of this mixture was used for each
ml of cell culture to be transfected. Small scale
transfections (4 ml) were performed in 6-well plates,
large scale transfections were performed in a 3L
Erlenmeyer flask (Corning, NY).
2.5. Purification of cLL
The supernatant of transfected HEK293-EBNA
cells was collected after 6 days and concentrated to a
final volume of approximately 250 ml using a hollow
fiber column (molecular-mass cut-off 10 kDa, Amer-
sham Biosciences, Uppsala, Sweden). Purification of
cLL was performed by affinity chromatography
(adapted from van Eijk et al., 2002). Briefly, 1 ml
(bed-volume) mannan-sepharose (Sigma, St. Louis,
MO), equilibrated in 50 mM Tris–HCl, 5 mM CaCl2,
and 0.05% (v/v) Tween-80, pH 7.4 was added to
the supernatant and CaCl2 was added to a final
concentration of 5 mM. The mixture was stirred
overnight at 4 8C. Sepharose beads were washed with
25 ml washing buffer (50 mMTris–HCl, 5 mMCaCl2,
500 mM NaCl, 0.05% Tween-80, pH 7.4). This
washing procedure was repeated with 25 ml washing
buffer without Tween-80. cLL was eluted with 50 mM
Tris–HCl, 5 mM EDTA, pH 7.4. The eluted protein
was concentrated using Amicon Ultra centrifugal filter
units with a molecular weight cut-off of 10 kDa
(Millipore, Billerica, MA), after which the buffer was
changed to 5 mM Tris–HCl, 150 mM NaCl, pH 7.4 by
repetitive washing. Purified cLL was stored in aliquots
at 20 8C.
2.6. Electrophoresis and Western blot analysis
Proteins (0.1–1 mg/lane) were analyzed by SDS-
PAGE as described by Laemmli (1970) using 10%
polyacrylamide gels. Protein bands were visualized
by Coomassie staining. For immunoblot analysis,
proteins (0.1–1 mg/lane) were transferred electro-
phoretically from the gels onto nitrocellulose
membrane. Immunostaining was performed using
mouse anti-His6 monoclonal antibody (Roche Diag-
nostics Gmbh, Mannheim, Germany). Primary anti-
bodies were detected by peroxidase-conjugated goat
anti-rabbit immunoglobulin G (IgG) (Sigma, St.
Louis, MO).
2.7. Enzymatic deglycosylation of cLL
N-deglycosylation treatment of cLLwas performed
using N-glycanase1 PNGase F (ProZyme, Inc., San
Leandro, CA) according to the manufacturer’s
instructions. Briefly, 45 ml cLL (230 mg/ml) was
mixed with 10 ml incubation buffer (0.25 M sodium
phosphate, pH 7.0) and 2.5 ml denaturation solution
(2% SDS and 1 M b-mercaptoethanol). The sample
was heated to 100 8C for 5 min, after which the sample
was cooled and 2.5 ml detergent solution (15%NP-40)
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was added. 2 ml of N-glycanase (5 U/ml) was added,
and after 16 h incubation at 37 8C, samples were
concentrated using Microcon centrifugal filter units
(MWCO 10 kDa) (Millipore, Billerica, MA). Samples
were immediately processed for further analysis. O-
deglycosylation treatment was performed using 1 ml
0.5 mU/ml O-glycosidase (Roche Diagnostics Gmbh,
Mannheim, Germany) according to the protocol used
for N-glycanase-PNGase. However, for O-glycosidase
treatment the cLL storage buffer was changed to
phosphate buffer (pH 7.0) using Microcon centrifugal
filter units (MWCO 10 kDa) (Millipore, Billerica,
MA). Deglycosylation by both N-glycanase-PNGase
and O-glycosidase was carried out similarly to O-
deglycosylation, but in this case both enzymes were
added simultaneously.
2.8. DIG-glycan detection
To assess possible glycosylation of cLL and
enzymatically treated cLL, the DIG-glycan detection
kit (Roche Diagnostics Gmbh, Mannheim, Germany)
was used according to the manufacturer’s instructions.
Briefly, samples containing cLL were loaded onto gel
and subsequently transferred from the gel onto
nitrocellulose membrane.
The presence of glycoconjugates was assessed by
labeling oxidized sugars with DIG-0-3-succinyl-e-
aminocaproic acid hydrazide, which was subsequently
detected using anti-digoxigenin-AP and staining with
NBT/X-phosphate.
2.9. Bis (sulfosuccinimidyl) suberate (BS3)-
crosslinking of cLL
Crosslinking of cLL using Bis (sulfosuccinimidyl)
suberate (BS3) (Pierce, Rockford, IL) was performed
according to the manufacturer’s instructions. Briefly,
the cLL storage buffer was changed to 10 mMHEPES
buffer, pH 7.5 containing 3 mM EDTA using
Microcon centrifugal filter units (MWCO 10 kDa)
(Millipore, Billerica, MA). Final concentration of cLL
was approximately 170 mg/ml. BS3 (50 mM) was
added to the protein solution and incubated at room
temperature for 30 min. The reaction was stopped by
adding SDS-PAGE sample buffer to the mixture,
which was subsequently heated to 100 8C and loaded
onto the gel for further analysis.
2.10. Maldi TOF-TOF
After protein separation on 12% SDS-PAGE and
fixation in 50%methanol and 7% acetic acid, cLL was
visualized using GelCode Blue Stain reagent (Pierce,
Rockford, IL). The four visible bands were cut from
the gel individually and subjected to in-gel tryptic
digestion as previously described by van Balkom et al.
(2005). Subsequently, these bands were identified by
matrix-assisted laser desorbtion/ionization (MALDI)
TOF-TOF analysis. The samples, dissolved in 0.1%
acetic acid, were concentrated using mC18-ZipTips
(Millipore) and eluted directly on the target plates in
1 ml of a saturated solution of R-cyano-4-hydroxy-
cinnamic acid in 50% (v/v) acetonitrile. Data were
acquired on a MALDI TOF-TOF instrument (Applied
Biosystems 4700 Proteomics Analyzer) in positive
reflectron mode at a laser intensity of 3800 and a bin
time of 0.5 ns.
2.11. Carbohydrate specificity
Polyacrylamide (PAA)-coupled glycoconjugates
(20% substitution; Lectinity, Lappeenranta, Fin-
land) were coated (5 mg/ml) in 0.2 M sodium
cacodylate buffer (pH 9.2) on NUNC maxisorb plates
(NUNC, Roskilde, Denmark) overnight at 4 8C. Plates
were blocked with 1% ELISA-grade BSA (Fraction V,
fatty acid free; Calbiochem, San Diego, USA) in TSM
(20 mM Tris–HCl pH 7.4, 150 mM NaCl, 2 mM
CaCl2, 2 mM MgCl2) and cLL was added (10 mg/ml)
for 2–3 h at 37 8C in the presence or absence of
10 mM EDTA. After washing with TSM containing
0.1% Tween-20, 1 mg/ml anti-His6 antibody (Roche
Diagnostics Gmbh, Mannheim, Germany) was
added for 1 h at room temperature. Binding was
detected using a peroxidase-labeled anti-mouse IgG
antibody (Jackson, West grove, PA, USA) and
measured in a Benchmark Microplate Reader using
the Microplate Manager software (both from Biorad,
Hercules, CA).
2.12. Testing the activity of cLL against human
isolates of IAV
2.12.1. Virus preparations
IAV was grown in the chorioallantoic fluid of 10-
day-old chicken eggs and purified on a discontinuous
A. Hogenkamp et al. / Veterinary Microbiology 130 (2008) 37–4640
sucrose gradient as described previously by Hartshorn
et al. (1988). Virus stocks were dialyzed against PBS,
aliquoted, and stored at 70 8C. A/Phillipines/82
(H3N2) (Phil), and its bovine serum b inhibitor-
resistant variant Phil/BS, were provided by Dr. E.M.
Anders (Department of Microbiology, University of
Melbourne, Melbourne, Australia). A/Puerto Rico/8/
34 (H1N1) (PR-8), which lacks the high-mannose
glycans on the haemagglutinin molecule, was pro-
vided by Dr. J. Abramson (Department of Pediatrics,
Bowman Gray School of Medicine, Wake Forest
University, Winston Salem, NC).
2.12.2. Neutralization of infectivity
Madin-Darby canine kidney (MDCK) cell mono-
layers were prepared in 96-well plates and grown to
confluence. These layers were then infected with a
PBS++ (PBS with 1 mM calcium and 0.5 mM
magnesium; Gibco BRL, Grand Island, NY) diluted
IAV preparation (Phil strain) which was preincubated
for 30 min at 37 8C in the presence or absence
(control) of increasing amounts of cLL. After
exposure of the MDCK cells to the IAV or IAV/cLL
mixture for 30 min at 37 8C, the cells were washed
three times in serum-free DMEM (Gibco BRL, Grand
Island, NY) containing 1% (w/v) penicillin–strepto-
mycin and subsequently incubated for 7 h at 37 8C.
Next, the monolayers were washed, fixed, and FITC-
labeled for IAV nucleoprotein as described previously
by Hartshorn et al. (2002), after which fluorescent foci
were counted.
2.12.3. Haemagglutination-inhibition assay
Haemagglutination (HAA)-inhibition was mea-
sured by serially diluting cLL preparations in
round-bottom 96-well plates (Serocluster U-Vinyl
plates; Costar, Cambridge, MA) using PBS++ as
diluent (25 ml per well). After adding 25 ml of IAV
solution, giving a final concentration of 40 HAAU/ml
or 4 HAA U/well, the IAV/cLL mixture was
preincubated for 15 min, followed by the addition
of 50 ml of human erythrocyte suspension in PBS++.
The entire procedure was performed at room
temperature. The minimal concentration of cLL,
required to fully inhibit the HAA caused by the virus,
was determined by reading the plates after 2 h. HAA
was detected as the formation of a pellet of
erythrocytes.
2.13. Statistical analysis
Statistical analysis was performed using SPSS
Version 12.0.1 for Windows. Analysis of mean values
between groups was carried out using Levene’s test for
equality of variances. When equality of variance was
assumed, mean values between groups were compared
with an independent t-test, in which p <0.05 was
considered to indicate statistical significance.
3. Results
3.1. Production and characterization of
recombinant cLL
Preliminary results from the small scale transfec-
tions (not shown) showed that cLL was most
effectively secreted using the mature peptide sequence
ligated into the pABC-cystatin-hisN vector with a
cystatin signal peptide and an in-frame N-terminal
His-tag. Therefore, this vector was selected for large-
scale (1 L) transfections. The predicted amino-acid
sequence of cLL expressed in this vector is shown in
Fig. 1. Affinity purification of the recombinant protein
using mannan-sepharose yielded approximately 500–
800 mg of protein per 1L batch (Fig. 2a). Analysis of
the purified product on SDS-PAGE showed that four
different bands varying in size between approximately
22 kDa and 27 kDa were present. Western blot
analysis using anti-His6 antibody showed a positive
signal for all four bands (Fig. 2b) in the untreated cLL-
sample (lane 1) indicating that all four bands were
recombinant products. To identify whether different
glycosylation patterns of the protein could account for
the observed multiplet, a DIG-glycan staining was
performed. Results of this DIG-glycan detection are
shown in Fig. 2c and indicate that all of the four
recombinant protein bands contained sugar moieties.
However, enzymatic treatment with N-glycanase /
PNGase or O-glycanase of cLL did not result in a size
shift (lanes 2–6), that would indicate loss of sugar
moieties. The multimeric state of cLL was investi-
gated by crosslinking experiments using BS3. SDS
PAGE analysis of the crosslinked cLL showed that
monomeric cLL bands were not present anymore
while two distinct high-molecular weight bands
appeared upon BS3 treatment of cLL (Fig. 3).
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3.2. Analysis by MALDI-TOF-TOF
MALDI-TOF-TOF analysis was performed in
order to investigate the cause of appearance of four
bands. However, the spectra of the trypsin-digested
protein of all four bands were similar, and could not
explain the size difference observed on SDS-PAGE.
Several peaks in the spectra could be assigned to
sequences in the recombinant protein, including the N-
and C-terminus which were retrieved for all four bands
(data not shown).
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Fig. 2. Production and structural characterization of cLL. (A)
Coomassie staining of cLL eluted from mannan-sepharose beads.
(B) Western blot analysis of the eluted cLL and enzymatically
treated cLL using anti-His6. (C) DIG-glycan detection for both
Sham-treated and enzymatically treated cLL; (B and C) 1: untreated
cLL, 2: Sham-treated N-glycanase-PNGase, 3: N-glycanase-
PNGase-treated cLL, 4: N-glycanase-PNGase and O-glycosidase-
treated cLL, lane 5: O-glycosidase-treated cLL, and lane 6: Sham-
treatment O-glycosidase.
Fig. 3. BS-crosslinking of cLL. Left lane: untreated cLL; right lane:
crosslinked cLL.
Fig. 1. Predicted amino acid sequence of recombinant cLL. 1: extra Gly–Ser-residues added after signal peptide; 2: extra Gly–Ser-residues
added as a result of inserting the BamHI restriction site into the sequence; 3: extra alanine-residues added as a result of inserting the NotI
restriction site into the sequence.
3.3. Carbohydrate specificity
Carbohydrate specificity of cLL was tested by use
of PAA-coupled glycoconjugates. cLL was observed
to preferentially bind to a-mannose–PAA and
trimannose–PAA (Man3), but not to any of the other
glycoconjugates (Fig. 4). Binding to a-mannose–PAA
and Man3–PAA was also tested in the presence of
EDTA, which significantly reduced the binding,
indicating that cLL binding to a-mannose and
Man3 is calcium-dependent.
3.4. Testing the activity of cLL against human
isolates of IAV
3.4.1. Neutralization of infectivity
In order to investigate whether cLL was capable of
protecting MDCK cell monolayers from infection by
Phil-strain, Phil/BS-strain or PR-8 strain IAV, virus
preparations were preincubated with increasing con-
centrations of cLL prior to adding them to the cells. No
differences were observed in the number of fluor-
escent foci, indicating that cLL does not interfere with
infection of these cells (data not shown).
3.4.2. cLL mediated HAA-inhibition
In the HAA-inhibition-assay, cLL was capable of
inhibiting HA-activity of all three human isolates of
IAV tested. The mean concentrations at which
erythrocytes were no longer agglutinated by the virus
are depicted in Fig. 5. Phil/BS was inhibited at a much
lower concentration of cLL than its parent strain Phil.
Haemagglutination-activity of PR-8 was inhibited at a
concentration comparable to that of Phil.
4. Discussion
We previously reported the finding of cLL which,
based on sequence homology, was predicted to be a C-
type lectin (Hogenkamp et al., 2006). The sequence of
its CRD is most similar to SP-A, but cLL does not
contain a collagenous domain and therefore could not
be classified as a collectin. To our knowledge, this
protein lacks further similarity to other C-type lectins
and should therefore be regarded as a novel type of
lectin (Hogenkamp et al., 2006).
In this study, recombinant cLL was used to further
characterize structural and functional properties of
this lectin. It was found that cLL appeared as four
differently sized products on SDS-PAGE gel (Fig. 2a
and b). No potential GPI-modification sites were
found in the sequence, and since the sequence of cLL
does not contain any potential N-glycosylation sites, it
is highly unlikely that differential N-glycosylation
could account for the appearance of four products
instead of one. However, a positive signal was
observed for all bands using the DIG-glycan detection
kit (Fig. 2c). Aspecific DIG-labeling or staining may
explain this result. Accordingly, enzymatic treatment
with N-glycanase and/or O-glycosidase did not result
in a size shift (Fig. 2b and c), and no difference in
intensity of DIG-glycan staining was observed
between enzymatically treated samples. However, it
cannot be excluded that cLL contains sugar moieties
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Fig. 4. Carbohydrate specificity of cLL. cLL binds to a-mannose
and Man3 in a calcium-dependent manner. Man3: trimannose; LeX:
Lewis X; LeY: Lewis Y; LeA: Lewis A; H-type 2: Lewis H-type 2;
H-type 3: Lewis H-type 3; LN: Gal-b-GlcNAc; LDN: GalNAc-beta-
GlcNAc; chi-3: GlcNAc-GlcNAc-GlcNAc
Fig. 5. Haemagglutination-activity inhibition by cLL minimal con-
centration of cLL (mg/ml) necessary to inhibit HA-activity of human
isolates of IAV. Values are mean concentration  S.D. of three
separate experiments.
that are insufficiently removed by enzymatic treat-
ment. As for O-linked glycans, it is known that these
glycans are highly heterogeneous while in general O-
glycosidases show a restricted specificity for sub-
classes of O-linked sugars. Therefore, we can not
exclude the possibility that O-linked glycans are
indeed present and result in heterogeneity of the cLL
polypeptide chains as illustrated by results presented
in Fig. 2.
The four bands obtained by SDS-PAGE analysis on
purified cLLwere subjected toMALDI-TOF-TOF and
resulted in identical spectra in which the C- and N-
terminal fragments could be retrieved for all four
bands, identifying all bands as (isoforms of) cLL.
This method is rather stringent, therefore it is
possible that post-translational modifications are
removed during the procedure. Further analysis using
2D gel electrophoresis combined with liquid chro-
matography coupled to tandem mass spectrometry
(LC–MS/MS) may reveal what causes the differences
in mass. As this concerns a recombinant protein, it
would be very interesting to find out whether the same
size differences are present in native cLL.
In mammalian species, collectin monomers are
known to organize into higher order multimers
(Crouch et al., 1994; King et al., 1989). Crosslinking
cLL led to the formation of two high-molecular weight
products (Fig. 3), suggesting that this protein is
capable of forming higher order subunits. The
presence of heptad repeats in the cLL-amino acid
sequence could allow for the formation of trimeric
subunits (Hogenkamp et al., 2006), characteristic for
all C-type lectins. Furthermore, it is known that the
carbohydrate-binding activity of C-type lectins is
quite weak when they are in their monomeric form
(Kishore et al., 1996). During the procedure of
affinity-purifying cLL by use of mannan-sepharose
beads, the beads were washed twice with a relatively
large volume of washing buffer. These conditions
would most likely be too stringent if carbohydrate-
binding by cLL were weak, making it more likely that
this protein is present as a trimer or a higher
multimeric form.
Analysis of the carbohydrate specificity of cLL
revealed that the protein binds to a-mannose and
Man3 in a calcium-dependent manner, but other
carbohydrates tested (including galactose) were not
bound by cLL (Fig. 4). It is possible that the presence
of a Glu–Pro–Ser motif in the CRD of cLL accounts
for the relatively high specificity of cLL. Most other
mannose type-collectins contain a Glu–Pro–Asn motif
(Drickamer, 1992) and most SP-As contain a Glu–
Pro–Arg motif, whilst retaining their preference for
mannose over galactose (McCormack et al., 1994).
However, Drickamer (1992) showed that substitution
of one amino acid is enough to change the sugar
binding specificity of C-type lectins. It would be
interesting to determine if construction of a similar
Glu–Pro–Ser motif in other C-type lectins would
result in a comparable specificity for mannose.
The activity of cLL against human isolates of IAV
was tested in viral inhibition assays. In HAA-
inhibition assays cLL showed strong activity against
the Phil/BS strain (Fig. 5). Two other strains tested,
Phil strain and PR-8, were less susceptible to cLL
inhibition. The infection of MDCK cells by IAV could
not be inhibited by cLL which may be explained by
the, compared to collectins, relative weak interaction
of cLL with these IAV strains. The change in
equilibrium between cLL-bound and free virus
particles could result in a constant supply of free
IAVas MDCK cell infection draws free virus particles
from the medium. This may explain the discrepancy
between the results from the MDCK cell infections
and the HAA-inhibition assays.
It is not yet clear what mechanism underlies the
susceptibility of the different IAV strains with respect
to the inhibition of haemagglutination by cLL. The
Phil/BS strain (subtype H3N2) differs from the parent
Phil strain, in that the high-mannose oligosaccharide
overlying the sialic acid receptor-binding site of the
HA molecule is absent (Hartley et al., 1992). It is
possible that this reveals targets for cLL binding that
are not available in the parent strain, resulting in
increased binding. The PR-8 strain also lacks high
mannose glycans on the HA molecule (Schwarz and
Klenk, 1981), but since this concerns a H1N1 subtype
of IAV it is possible that differences in targets
available on the HA molecule or the neuraminidase
may result in decreased binding. It will be interesting
to see what mediates cLL binding to IAV, since
binding of SP-A (to which cLL is most similar) is
thought to occur via binding of the sialic acid receptor
of the virus to sialylated N-linked oligosaccharide
present in the CRD of SP-A (Benne et al., 1995). It is
possible that cLL, similar to SP-D (Hartshorn et al.,
A. Hogenkamp et al. / Veterinary Microbiology 130 (2008) 37–4644
2000), binds to HA and neuraminidase in a C-type
lectin-like manner, but the exact mechanism remains
to be elucidated.
5. Conclusion
The chicken lung lectin was successfully expressed
in HEK293-EBNA cells. The purified protein proved
to be a C-type lectin, as predicted from its sequence.
Analysis of its carbohydrate specificity revealed that
this protein has an unusual high preference for binding
a-mannose and trimannose. The results of the viral
inhibition assays showed that cLL has moderate HAA-
inhibition activity against the human IAV strains Phil
and PR-8 and a strong inhibitory activity against Phil/
BS. These results indicate that cLL could play an
important part in the innate immune system of
chickens.
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